Carcinomes urothéliaux, formes métastatiques: traitements médicaux d’aujourd’hui et de demain

Urothelial carcinoma remains one of the most common and lethal disease in males. The combination of gemcitabine plus cisplatin with the MVAC regimen is used as first-line chemotherapy for advanced urothelial carcinoma. For unfit patients, the combination of carboplatin and gemcitabine is the preferred option. Currently, there is no standard therapy for patients who failed after first-line platinum-based chemotherapy, although vinflunine has been approved in this setting. However, recent advances in understanding the biological background of urothelial carcinomas have led to new hopes in metastatic disease, mainly with the new immune checkpoint inhibitors (PD-1 and PDL1 inhibitors). Future strategies targeting the genomic alterations will be assessed in the coming years.